What is the primary objective of FDA 21 CFR Part 11?

The primary objective of FDA 21 CFR Part 11 is to establish criteria under which the FDA considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records and handwritten signatures (§11.1(a)). This equivalency enables electronic technology use while ensuring authenticity, integrity, confidentiality (when appropriate), and non-repudiation through controls like validation (§11.10(a)), audit trails (§11.10(e)), and signature linking (§11.70).

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

FDA 21 CFR Part 11 applies to organizations using electronic records created, modified, maintained, archived, retrieved, or transmitted under predicate rules, or relied upon for regulated activities. Scope includes predicate-rule-required records maintained electronically in lieu of paper, electronic records relied on despite paper existence, FDA-submitted records (per docket 92S-0251), and legally binding electronic signatures (§11.1(b)). Exclusions apply to certain food records (§11.1(f)–(p)) and paper transmitted electronically.

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal controls, validation, SOPs, and inspection readiness (§11.1(e)), with systems and documentation readily available for FDA review. FDA's 2003 guidance emphasizes predicate rule enforcement and risk-based approaches without mandating external validation.

How often should an assessment for FDA 21 CFR Part 11 be performed?

FDA 21 CFR Part 11 does not specify a fixed frequency for assessments; organizations must use risk-based periodic reviews integrated with change control and quality systems. Assessments occur during system changes, periodic reviews, or as needed for fitness-for-use, ensuring ongoing compliance with controls like validation (§11.10(a)) and documentation (§11.10(k)).

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 can result in FDA enforcement actions including Form 483 observations, warning letters, product holds, and predicate rule violations. The 2003 guidance notes continued enforcement of access controls, checks, training, signatures, and documentation, leading to data integrity issues, batch failures, and regulatory penalties.

Can FDA 21 CFR Part 11 be mapped to other international frameworks?

FDA 21 CFR Part 11 is not explicitly mapped to other frameworks in its text or 2003 guidance; compliance stands alone based on predicate rules. Organizations may align controls risk-based but must meet Part 11 specifics like closed/open system distinctions (§11.10, §11.30) independently.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step to implement FDA 21 CFR Part 11 is to establish a formal applicability framework mapping predicate rules to records and assessing business reliance on electronic versions. Document decisions in SOPs (§11.1(b)), classify systems as closed or open (§11.3(b)(4),(9)), and prioritize enforced controls like access limitation (§11.10(d)).

What is the primary objective of MLPS 2.0 (Multi-Level Protection Scheme)?

MLPS 2.0 (Multi-Level Protection Scheme) establishes a graded cybersecurity framework to protect information systems based on potential impact to national security, social order, and public interests. It classifies systems into five levels (1-5), with controls scaling from basic self-protection at Level 1 to stringent measures at Level 5 for military systems. Originating from China's 2017 Cybersecurity Law (Article 21), it ensures commensurate security via technical, management, physical, and personnel requirements across domains like network boundaries, data protection, and governance.

Who is legally or professionally required to comply with MLPS 2.0 (Multi-Level Protection Scheme)?

All network operators in mainland China, including domestic firms, foreign-invested enterprises, and multinationals, must comply with MLPS 2.0 (Multi-Level Protection Scheme). This covers virtually any entity operating IT systems, cloud services, IoT, big data, or industrial controls. Critical sectors like finance, energy, telecom classify at Level 3+, with PSBs enforcing via inspections and license renewals.

Does MLPS 2.0 (Multi-Level Protection Scheme) require an external audit or third-party certification?

Yes, MLPS 2.0 (Multi-Level Protection Scheme) mandates external security reviews by licensed Chinese firms for Level 2+ systems, scoring at least 70/100 for certification. Operators submit results to PSBs for approval; Level 3+ requires detailed documentation like architectures and risk assessments. Level 1 needs only self-assessment.

How often should an assessment for MLPS 2.0 (Multi-Level Protection Scheme) be performed?

MLPS 2.0 (Multi-Level Protection Scheme) requires re-evaluations scaling by level: biennially for Level 2, annually for Level 3, semi-annually for Level 4, and as mandated for Level 5. Triggered by major changes (e.g., cloud migration), assessments include self-inspections, third-party audits, and PSB oversight to maintain certification.

What are the consequences of non-compliance with MLPS 2.0 (Multi-Level Protection Scheme)?

Non-compliance with MLPS 2.0 (Multi-Level Protection Scheme) results in fines up to 100,000 yuan, operational suspensions, system shutdowns, and intensified PSB inspections. Enforcement links to license renewals; severe cases involve blacklisting or criminal liability, as seen in multimillion-yuan fines under associated data laws for breaches tied to inadequate protections.

Can MLPS 2.0 (Multi-Level Protection Scheme) be mapped to other international frameworks?

Yes, MLPS 2.0 (Multi-Level Protection Scheme) maps to frameworks like ISO 27001 and NIST CSF via shared domains such as organizational controls, physical security, and technical baselines. Its governance (e.g., roles, policies) aligns with ISO Annex A; risk-based grading complements NIST tiers. Organizations extend existing ISMS Statements of Applicability for MLPS compliance.

What is the first step to begin implementing MLPS 2.0 (Multi-Level Protection Scheme)?

The first step for MLPS 2.0 (Multi-Level Protection Scheme) implementation is conducting a provisional self-assessment to classify systems into Levels 1-5 based on impact to national security, social order, and public interests. Inventory assets, evaluate harm severity, document rationale, then file with PSBs (within 30 days for Level 2+), engaging experts for validation.

Standards Comparison

FDA 21 CFR Part 11 vs MLPS 2.0 (Multi-Level Protection Scheme)

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation for electronic records/signatures equivalency

MLPS 2.0 (Multi-Level Protection Scheme)

Mandatory

2019

China's mandatory graded cybersecurity protection framework

Quick Verdict

FDA 21 CFR Part 11 ensures trustworthy electronic records for US life sciences, while MLPS 2.0 mandates graded cybersecurity for all Chinese networks. Companies adopt Part 11 for FDA compliance; MLPS for legal operations in China.

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11: Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

Medium

Implementation Time

12-18 months

Key Features

Equivalency criteria for electronic records to paper
Secure time-stamped audit trails for changes
Unique non-repudiable electronic signatures
Differentiated controls for closed/open systems
Risk-based validation with enforcement discretion

Cybersecurity

MLPS 2.0 (Multi-Level Protection Scheme)

Multi-Level Protection Scheme 2.0 (MLPS 2.0)

Cost

€€€€

Complexity

Medium

Implementation Time

12-18 months

Key Features

Five-level impact-based system classification
Mandatory PSB registration and approval for Level 2+
Technical controls for cloud, IoT, big data
Third-party audits with 70/100 passing score
Governance and personnel segregation requirements

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule records. The risk-based approach narrows scope to relied-upon electronic records, with enforcement discretion on some controls.

Key Components

**Subpart BControls for closed (§11.10) and open (§11.30) systems, including validation, audit trails, access limits, checks, signatures linking.
**Subpart CElectronic signature uniqueness, manifestation (§11.50), components (§11.200), ID/password controls (§11.300).
Core principles: authenticity, integrity, non-repudiation; ~20 key controls; compliance via validation, SOPs, no formal certification.

Why Organizations Use It

Ensures regulatory acceptance of digital records, mitigates enforcement risks like warning letters, supports data integrity for quality decisions. Mandatory for electronic reliance in pharma, devices, biologics; builds trust, enables efficiency.

Implementation Overview

Risk-based CSV (IQ/OQ/PQ), scoping via predicate mapping, vendor governance. Applies to life sciences globally under FDA; involves SOPs, training, audits; 12-18 months typical for mid-size firms.

MLPS 2.0 (Multi-Level Protection Scheme) Details

What It Is

MLPS 2.0 (Multi-Level Protection Scheme 2.0) is China's legally mandated cybersecurity regulation under the 2017 Cybersecurity Law (Article 21). It is a graded protection framework requiring network operators to classify systems into five levels based on compromise impact to national security, social order, and public interests. Scope covers all networks in mainland China, including IT, cloud, IoT, big data, and industrial controls.

Key Components

Five protection levels with escalating technical (network, data, access), management (governance, policies), physical, and personnel controls.
Core standards: GB/T 22239-2019 (basics), GB/T 25070-2019 (technical), GB/T 28448-2019 (evaluation).
Common baselines plus extended requirements for emerging tech; compliance via PSB filing, third-party audits (70/100 score minimum for Level 2+).

Why Organizations Use It

Mandatory compliance avoids fines, license suspensions, inspections by Public Security Bureaus.
Enhances risk management, resilience; aligns with data laws (DSL, PIPL).
Builds regulator trust, enables market access in China.

Implementation Overview

Phased: classify systems, gap analysis, remediate, external audit, PSB approval. Applies to all China-based operators; higher levels need annual re-evals. Costs tens of thousands USD/year for Level 3.

Key Differences

Aspect	FDA 21 CFR Part 11	MLPS 2.0 (Multi-Level Protection Scheme)
Scope	Electronic records/signatures trustworthiness	Graded cybersecurity for all networks/systems
Industry	FDA-regulated life sciences, US-focused	All network operators in China, broad sectors
Nature	US federal regulation, enforcement discretion	Mandatory Chinese law, PSB enforcement
Testing	Risk-based validation, audit trails	Third-party audits, level-specific evaluations
Penalties	Warning letters, product holds	Fines, operational suspension, inspections

Scope

FDA 21 CFR Part 11

Electronic records/signatures trustworthiness

MLPS 2.0 (Multi-Level Protection Scheme)

Graded cybersecurity for all networks/systems

Industry

FDA 21 CFR Part 11

FDA-regulated life sciences, US-focused

MLPS 2.0 (Multi-Level Protection Scheme)

All network operators in China, broad sectors

Nature

FDA 21 CFR Part 11

US federal regulation, enforcement discretion

MLPS 2.0 (Multi-Level Protection Scheme)

Mandatory Chinese law, PSB enforcement

Testing

FDA 21 CFR Part 11

Risk-based validation, audit trails

MLPS 2.0 (Multi-Level Protection Scheme)

Third-party audits, level-specific evaluations

Penalties

FDA 21 CFR Part 11

Warning letters, product holds

MLPS 2.0 (Multi-Level Protection Scheme)

Fines, operational suspension, inspections

Frequently Asked Questions

Common questions about FDA 21 CFR Part 11 and MLPS 2.0 (Multi-Level Protection Scheme)

FDA 21 CFR Part 11 FAQ

MLPS 2.0 (Multi-Level Protection Scheme) FAQ

You Might also be Interested in These Articles...

The SOC Maturity Roadmap: A 5-Step Blueprint for Scaling from Ad-Hoc to Optimized Operations

Unlock SOC excellence with our 5-step maturity roadmap. Compare SOC-CMM, NIST CSF, and CMMC frameworks to scale from ad-hoc to automated operations. Start your

CIS Controls v8.1 for Cloud & Kubernetes: A Practical Implementation Playbook (AWS/Azure/GCP + IaC)

Translate CIS Controls v8.1 to cloud-native: Kubernetes patterns for IAM, logging, vuln mgmt, hardening on AWS, Azure, GCP + IaC. Practical playbook for teams.

DORA Third-Party Risk Management: A Consultant’s Guide to Mapping Critical ICT Service Providers in 2026

Navigate DORA's complex third-party risk pillar. Step-by-step consultant guide to identify critical ICT providers, remediate Article 30 contracts, and build the

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how FDA 21 CFR Part 11 and MLPS 2.0 (Multi-Level Protection Scheme) compare against other standards

Other FDA 21 CFR Part 11 Comparisons

Other MLPS 2.0 (Multi-Level Protection Scheme) Comparisons

What It Is

Key Components

**Subpart BControls for closed (§11.10) and open (§11.30) systems, including validation, audit trails, access limits, checks, signatures linking.

**Subpart CElectronic signature uniqueness, manifestation (§11.50), components (§11.200), ID/password controls (§11.300).

Core principles: authenticity, integrity, non-repudiation; ~20 key controls; compliance via validation, SOPs, no formal certification.

What It Is

Key Components

Five protection levels with escalating technical (network, data, access), management (governance, policies), physical, and personnel controls.

Core standards: GB/T 22239-2019 (basics), GB/T 25070-2019 (technical), GB/T 28448-2019 (evaluation).

Common baselines plus extended requirements for emerging tech; compliance via PSB filing, third-party audits (70/100 score minimum for Level 2+).

Aspect

FDA 21 CFR Part 11

MLPS 2.0 (Multi-Level Protection Scheme)

Scope

Electronic records/signatures trustworthiness

Graded cybersecurity for all networks/systems

Industry

FDA-regulated life sciences, US-focused

All network operators in China, broad sectors

Nature

US federal regulation, enforcement discretion

Mandatory Chinese law, PSB enforcement

Testing

Risk-based validation, audit trails

Third-party audits, level-specific evaluations

Penalties

Warning letters, product holds

Fines, operational suspension, inspections